Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Other Non-Interest Income (2016 - 2022)

Historic Other Non-Interest Income for BioRestorative Therapies (BRTX) over the last 12 years, with Q2 2022 value amounting to $245.0.

  • BioRestorative Therapies' Other Non-Interest Income fell 9606.11% to $245.0 in Q2 2022 from the same period last year, while for Jun 2022 it was $9935.0, marking a year-over-year increase of 1075.81%. This contributed to the annual value of $12290.0 for FY2021, which is 5654.33% down from last year.
  • According to the latest figures from Q2 2022, BioRestorative Therapies' Other Non-Interest Income is $245.0, which was down 9606.11% from $469.0 recorded in Q1 2022.
  • In the past 5 years, BioRestorative Therapies' Other Non-Interest Income ranged from a high of $156179.0 in Q3 2019 and a low of $150.0 during Q3 2020
  • Over the past 5 years, BioRestorative Therapies' median Other Non-Interest Income value was $11028.5 (recorded in 2019), while the average stood at $42147.1.
  • Its Other Non-Interest Income has fluctuated over the past 5 years, first surged by 212039.21% in 2018, then crashed by 9990.4% in 2020.
  • Quarter analysis of 5 years shows BioRestorative Therapies' Other Non-Interest Income stood at $138489.0 in 2018, then grew by 12.77% to $156179.0 in 2019, then crashed by 99.9% to $150.0 in 2020, then skyrocketed by 2013.33% to $3170.0 in 2021, then plummeted by 92.27% to $245.0 in 2022.
  • Its Other Non-Interest Income stands at $245.0 for Q2 2022, versus $469.0 for Q1 2022 and $3170.0 for Q4 2021.